Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07020923 · ClinicalTrials.gov registry record · Phase 2
Monthly Dosing of Atacicept in IgAN
A Phase 2 study of IgA Nephropathy (IgAN) and Berger Disease, sponsored by Vera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07020923 is a Phase 2 study of IgA Nephropathy (IgAN) and Berger Disease that is actively recruiting participants, run by Vera Therapeutics. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07020923, a Phase 2 study of IgA Nephropathy (IgAN) and Berger Disease, is actively recruiting participants, sponsored by Vera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Conditions Studied
Interventions
- DRUG Atacicept
Study Locations (1)
California
- Vera Therapeutics - Brisbane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-05-29 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07020923
The ClinicalTrials.gov registry entry for NCT07020923 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vera Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with IgA Nephropathy (IgAN) appearing as the primary indexed condition, and to 1 intervention - of which Atacicept is the first listed.
NCT07020923 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07020923 about?
NCT07020923 is a clinical study titled "Monthly Dosing of Atacicept in IgAN". This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
What is the current status of trial NCT07020923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-05-29. Estimated completion is 2027-09.
What conditions does trial NCT07020923 study?
This clinical trial studies the following conditions: IgA Nephropathy (IgAN), Berger Disease.
What interventions are being tested in trial NCT07020923?
The interventions under investigation include: Atacicept (DRUG).
Who is sponsoring clinical trial NCT07020923?
This trial is sponsored by Vera Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07020923 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy (IgAN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.